Sialylation of FGFR1 by ST6Gal-I overexpression contributes to ovarian cancer cell migration and chemoresistance

LINGLING OU1*, XIUZHEN HE2*, NAIHUA LIU3, YUWEI SONG1, JINYUAN LI1, LYNEN GAO1, XINKE HUANG1, ZHENDONG DENG3, XIAOYU WANG1 and SHAOQIANG LIN3,4

1Department of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632; 2Chongqing Three Gorges Medical College, Chongqing 404120; 3Integrated Traditional and Western Medicine Research Center of The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510000; 4School of Pharmaceutical Sciences of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China

Received January 11, 2019; Accepted August 5, 2019

DOI: 10.3892/mmr.2020.10951

Abstract. Fibroblast growth factor receptors (FGFRs) have been implicated in the malignant transformation and chemoresistance of epithelial ovarian cancer; however, the underlying molecular mechanisms are poorly understood. Increased sialyltransferase activity that enhances protein sialylation is an important post-translational process promoting cancer progression and malignancy. In the present study, α2,6-sialyltransferase (ST6Gal-I) overexpression or knock-down cell lines were developed, and FGFR1 was examined to understand the effect of sialylation on migration and drug resistance, and the underlying mechanisms. It was identified that cells with ST6Gal-I overexpression had increased cell viability and migratory ability upon serum deprivation. Moreover, ST6Gal-I overexpression cells had strong resistance to paclitaxel, as demonstrated by low growth inhibition rate and cell apoptosis level. A mechanistic study showed that ST6Gal-I overexpression induced high α2,6-sialylation of FGFR1 and increased the expression of phospho-ERK1/2 and phospho-focal adhesion kinase. Further study demonstrated that the FGFR1 inhibitor PD173047 reduced cell viability and induced apoptosis; however, ST6Gal-I overexpression decreased the anticancer effect of PD173047. In addition, ST6Gal-I overexpression attenuated the effect of Adriamycin on cancer cells. Collectively, these results suggested that FGFR1 sialylation plays an important role in cell migration and drug chemoresistance in ovarian cancer cells.

Introduction

Fibroblast growth factor receptors (FGFRs), which belong to the receptor tyrosine kinase (RTK) family, are known to signal from the cell membrane as well as from endosomal compartments (1). There are four FGFRs: FGFR1, FGFR2, FGFR3 and FGFR4; these FGFs bind their receptors and >20 known ligands to these receptors, resulting in diverse effects in many different target cells (2). FGFR signaling plays an important role in cell proliferation, angiogenesis and many normal biological processes (3); however, FGFR signaling dysregulation has been implicated in aberrant pathologies associated with tumor growth, including ovarian, colon, breast, prostate, soft tissue sarcomas, melanoma and lung cancer (4-9).

Despite advances in treatment over the past decades, ovarian cancer has the highest mortality among gynecologic malignancies (10). Limited prognosis remains a key obstacle for the treatment of patients with advanced ovarian cancer (11). Upregulation of all four members of the FGFR family and other various fibrolast growth factors has been found in epithelial ovarian carcinoma tissue (10,12), suggesting that dysregulated FGFR signaling contributes to ovarian carcinogenesis and may represent a suitable therapeutic target (13). The FGFR4 GlyArg388 polymorphism has been shown to predict prolonged survival and platinum sensitivity in advanced ovarian cancer (14). FGFR1 and FGFR2 mutations have also been demonstrated to promote ovarian cancer progression and invasion (15,16). The mechanisms of FGFR1 in other cancer types have been studied; for example, the upregulation of FGFR1 in carcinoma cells is critical for prostate cancer progression and invasion (17). Furthermore, the FGFR1
pathway recruits macrophages to the mammary epithelium and promotes paracrine interactions between tumor cells and macrophages, thus inducing tumor growth (18,19). However, to the best of the authors' knowledge, not many studies on the role of FGFR1 in ovarian cancer exist, and how FGFR1 functions in ovarian cancer is unclear.

Genetic evidence and structure analysis indicated that the N-glycosylation of FGFR1 may constitute an important regulatory input (20). The disruption of N-glycosylation can cause the mutation of an asparagine residue in the extracellular domain of FGFR2 and FGFR3, and result in skeletal growth defects. Abnormal cellular glycosylation has been shown to play a key role in cancer progression and malignancy (21-23). Therefore, understanding the regulation of FGFR glycosylation may provide novel insight into cancer biology and result in developing possible therapeutic strategies. Glycosylation is regulated by various glycosyltransferases, such as fucosyl-, sialyl- and galactosyltransferases (24). The β-galactoside α2,6-sialyltransferase, CMP-NeuAc: Galβ1(1,4) GlcNAc: α2,6-sialyltransferase (ST6Gal-I) is a vital sialyltransferase that adds sialic acid residues to N-linked oligosaccharides (25). ST6Gal-I has been reported to induce adhesion and migration, and promote drug resistance in various cancer cells (26-29). However, the possible biological effect of ST6Gal-I on FGFR1 in ovarian cancer has not been clearly established.

In the present study, ST6Gal-I knockdown or overexpression OVCAR3 ovarian cell lines were prepared and characterized, to investigate the sialylation of FGFR1 and its effects on cancer cell proliferation and migration, and sensitivity to anticancer drugs. It was identified that ST6Gal-I overexpression induced high sialylation levels of FGFR1, and activated ERK and focal adhesion kinase (FAK) signaling in cells. ST6Gal-I overexpression decreased the effects of anticancer drugs, but ST6Gal-I knockdown resulted in the opposite effect. Collectively, these data suggested that FGFR1 sialylation affects FGFR1-mediated cell growth and chemotherapeutic drug sensitivity in human ovarian cancer cells. FGFR1 sialylation levels are hypothesized to be a reliable biomarker for anti-FGFR1 therapy.

Materials and methods

Cell culture and transfection. OVCAR3 ovarian cancer cells, purchased from The American Type Culture Collection, were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C in a 5% CO₂ humidified atmosphere. Stable ST6Gal-I overexpression (oe-ST6Gal-I), knockdown small hairpin-ST6Gal-I (sh-ST6Gal-I) or empty vector cell lines were established, as previously described (30). In brief, pcDNA3.1(-)/ST6Gal-I, small hairpin (sh)-ST6Gal-I and empty vector plasmids (10 µg/ml) were purchased from Invitrogen; Thermo Fisher Scientific, Inc., and transfected into OVCAR3 ovarian cancer cells with Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.). A limiting dilution was applied to obtain subcell line clones after 24 h of transfection. Blasticidin S HCl (1.5 µg/ml, Invitrogen; Thermo Fisher Scientific, Inc.) was utilized to select the ST6Gal-I overexpression clone. ST6Gal-I overexpression or knockdown cell lines were verified by reverse transcription (RT)-semi-quantitative (q)PCR and immunoblotting.

RT-qPCR. Total RNA was isolated from the cells using TRizol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and cDNA was synthesized using a PrimeScript RT Master Mix kit (Takara Bio) according to the manufacturer’s protocol: 37˚C for 60 min, 85˚C for 5 min and hold at 4˚C. RT-qPCR was performed on a Real-Time PCR Detection System (Bio-Rad Laboratories). PCR cycles were: Pretreatment at 95˚C for 10 min, 93˚C for 15 sec, 67˚C for 45 sec (45 cycles), then 93˚C for 15 sec, 67˚C for 1 min, 95˚C for 15 sec, 75˚C for 10 min and hold at 4˚C. The primer sequences used for the real-time PCR assays were as follows: Forward, 5’- CCTCTGGGATGC TTGGTATC-3’; and reverse, 5’- GTGCAGGCATCTACG AAAGA-3’ for ST6Gal-I; forward, 5’- AGCTCTCAAGATC ATCAGC-3’ and reverse, 5’- GAGCTCCTTCACAGTACC-3’ for GAPDH (BGI, Inc.). The gene expression was determined using the 2-ΔΔcq method (31).

ST6Gal-I activity assay. Lectin staining was conducted to measure ST6Gal-I activity. Cells were stained with FITC-conjugated SNA lectin (EY Laboratories, Inc.), which is specific for 2-6 sialic acids. Cells were stained for 40 min at 4˚C with SNA-FITC (1:200) and analyzed by fluorescence-activated cell sorting (FACS; Becton Dickinson). In addition, cells were stained with SNA-FITC (1:100) for 4 h at room temperature for an immunofluorescence assay using a Leica DM2500 LED microscope (Leica Microsystems GmbH) at 200x magnification.

Scratch wound healing assay. After the oe-ST6Gal-I and sh-ST6Gal-I subcell line clones were verified, a wound healing assay was used to assess cell migration (32). Cells (10⁴ cells/well) were seeded in a 6-well plate, and the tip of a 200-µl micropipette was used to make a straight scratch on a confluent monolayer of cells to create a wound. The detached cells were rinsed with PBS twice, and serum-free DMEM was then added. The wound closure in the area was imaged in brightfield using a microscope (Olympus Corporation; magnification, x100) after incubation for 0, 12 and 24 h. The wound closure areas were selected randomly and the width of the wound was quantified in ImageJ (v1.8, National Institutes of Health) to show the wound closure at each time point. The results of four independent experiments were imaged under a microscope and quantified.

Cell Counting Kit-8 (CCK-8) assay. To measure the proliferation of different transfected cloned cell lines, a CCK-8 detection kit (Dojindo Molecular Technologies, Inc.) was used, according to the manufacturer’s protocol. In total, ~3,000 cells were seeded into a 96-well plate in quintuplicate for 6 h, and complete medium was then changed to DMEM with different concentrations (0, 10, 100, 1,000 and 10,000 nM) of paclitaxel, Adriamycin or PD173074 (Sigma-Aldrich; Merck KGaA) for 24 h or the cells were cultured without FBS for 0, 24, 48, 72, 96, 120 and 144 h at 37˚C. Next, 10 µl CCK-8 reagent was added to each well, and the absorbance value was measured.
at 490 nm using a Multiskan Spectrum spectrophotometer (BioTek Instruments, Inc.).

**Apoptosis analysis by flow cytometry.** Cells were incubated with different concentrations of paclitaxel, Adriamycin or PD173074 (Sigma-Aldrich; Merck KGaA) for 24 h and collected for staining. After centrifugation at 200 x g at 4°C, the cell pellets were resuspended and placed in 100 µl Annexin V binding buffer containing 5 µl Annexin V-Phycoerythrin (PE) and 2 µl 7-aminoactinomycin D (7-AAD; BD Biosciences). The cells were incubated with PE-labeled Annexin V binding buffer in the dark at room temperature for 20 min. Staining controls were prepared and were single-stained or unstained. A positive apoptotic control was obtained by incubating cells for 15 h with 1 mM hydrogen peroxide (Sigma–Aldrich; Merck KGaA). The stained cell populations were analyzed using a FACSCalibur flow cytometer (BD Biosciences), and the cell cycle distributions were analyzed using FlowJo software v10 (FlowJo LLC).

**Immunoprecipitation and immunoblotting.** Cells were lysed using cell lysis buffer (PBS, 1% NP40, 1% sodium deoxycholate and 0.1% SDS, 100 µg/ml PMSF, 1 mM sodium orthovanadate and 1 protease inhibitor tablet/10 ml), and the protein concentration was measured using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology). Equal amounts of denatured proteins (20 µg) were separated by SDS-PAGE on 10% gels and transferred onto PVDF membranes. Antibodies against ST6Gal-I (1:200, cat. no. AF5924, R&D Systems), FGFR1 (1:200, cat. no. ab156031, Abcam), phosphorylated (p)-FGFR1 (1:200, cat. no. ab59194, Abcam), ERK (1:200, cat. no. sc514302, Santa Cruz Biotechnology), p-ERK (1:200, cat. no. sc156521, Santa Cruz Biotechnology), FAK (1:200, cat. no. ab72140, Abcam), p-FAK (1:200, cat. no. ab4792, Abcam), cleaved caspase-3 (1:200, cat. no. ab49822, Abcam) and GAPDH (1:1,000, cat. no. sc23233, Santa Cruz Biotechnology, Inc.) were used as the primary antibodies. For SNA-FGFR1, 100 µl SNA-conjugated agarose (EY Laboratories, Inc.) was added to the lysed protein for 1 h, and the beads were collected. α2,6-sialylated proteins bound to SNA-agarose beads were precipitated by centrifugation (200 x g) at 4°C for 10 min and washed extensively with lysis buffer. Sialylated proteins were released from the complexes and then boiled in SDS-PAGE sample buffer and immunoblotted for FGFR1 (Santa Cruz Biotechnology, Inc.). The membranes were blocked with 5% non-fat milk at room temperature, and then incubated with a primary antibody and horseradish peroxidase-conjugated secondary antibody (Goat IgG Horseradish Peroxidase-conjugated Antibody, cat. no. HA0F019, R&D Systems, Oakville, Canada; Mouse IgG Horseradish Peroxidase-conjugated Antibody, cat. no. sc516132, Santa Cruz Biotechnology, Inc.; Rabbit IgG Horseradish Peroxidase-conjugated Antibody, cat. no. HAF008, R&D Systems Oakville, Canada), and detected using an ECL kit (GE Healthcare) according to the manufacturer’s protocol. The relative amount of protein was determined by densitometry using ImageJ software (version v1.8.0, National Institutes of Health).

**Statistical analysis.** All the experiments were repeated 3 times. The data are presented as the mean ± SD and analyzed by GraphPad Prism 6 (GraphPad Software Inc.). One-way ANOVA with the Least Significant Difference post hoc test was performed to determine statistical significance between groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Establishment of oe-ST6Gal-I or sh-ST6Gal-I subcell clones of OVCAR3 human ovarian cancer cells.** The majority of previous FGFR1 studies have focused on FGFR1 amplification and activating mutations (33-35), whereas regulation of FGFR1 activity via post-translational modifications, such as glycosylation, fucosylation and sialylation, has been studied considerably less. To the best of the authors’ knowledge, there are no studies that have investigated the relevance of FGFR1 α2,6-sialylation in the poor prognosis and treatment of ovarian cancer. Therefore, the present study aimed to evaluate the effects of ST6Gal-I on FGFR1 and ovarian cancer progression. An overexpressing plasmid and shRNA vector of ST6Gal-I were constructed and transfected into OVCAR3 cells. After limiting dilution and persistent culture, stable subcell line clones were established. The expression of ST6Gal-I was further confirmed by PCR and western blotting assays. The endogenous ST6Gal-I gene and protein were stably overexpressed in the oe-ST6Gal-I clone, whereas the ST6Gal-I gene and protein were decreased in the sh-ST6Gal-I cell line compared with their expression in the empty vector cell line (Fig. 1A-D). These data indicated that ST6Gal-I was stably overexpressed or knocked down in OVCAR3 cells.

To assess the effect of ST6Gal-I upregulation or downregulation on the FGFR1 receptor in tumor cells, FITC-conjugated SNA lectin was used to recognize α2,6-linked sialic acids by immunofluorescence microscopy. The immunofluorescence results showed that oe-ST6Gal-I cells expressed significantly higher levels of α2,6-linked sialic acids than vector cells; conversely, sh-ST6Gal-I cells expressed lower levels of α2,6-linked sialic acids than vector control cells (Fig. 1E and F).

**Cells with high ST6Gal-I expression enhance tumor cell viability and migratory ability.** To test whether ST6Gal-I expression affected ovarian cancer cell viability, a CCK-8 assay was conducted. It was observed that the growth rate and cell viability were markedly higher in oe-ST6Gal-I cells than in sh-ST6Gal-I cells and vector cells incubated with complete culture medium (Fig. 2A). To determine the role of ST6Gal-I in protecting against serum withdrawal, oe-ST6Gal-I, sh-ST6Gal-I and vector cells were cultured under serum starvation conditions for 0, 24, 48, 72, 96, 120 or 144 h. As shown in Fig. 2B, the CCK-8 results indicated that the growth inhibition rate and cytotoxicity were lower in oe-ST6Gal-I cells than in sh-ST6Gal-I cells. Additionally, scratch-wound healing assays were conducted to detect cell migration. The results showed that compared with vector cells, the increased ST6Gal-I expression in oe-ST6Gal-I cells significantly promoted cell migration, and the decreased ST6Gal-I expression in sh-ST6Gal-I cells significantly attenuated cell migration at 6, 12 and 24 h (Fig. 2C and D). Collectively, these results suggested that ST6Gal-I overexpression promoted the proliferation and migration of ovarian cancer cells.
Cells with high ST6Gal-I expression have reduced cell apoptosis and increased chemoresistance. To test the effect of ST6Gal-I expression status on the anticancer efficacy of paclitaxel, a cell viability assay and FACS analysis were performed in ovarian cancer cells. The data showed that the growth inhibition of paclitaxel was dose-dependent in each group. The growth inhibition was higher in sh-ST6Gal-I stable clone cells than in oe-ST6Gal-I cells at drug concentrations of 10-1,000 nM, and most of the cells died at the high concentration of 10 µM (Fig. 3A). Furthermore, PE-labeled Annexin V and 7-AAD staining were analyzed by FACS to determine cell apoptosis. The Annexin V receptor is a phosphatidylinerse, which is normally an asymmetric resident of the inner membrane. Only when its asymmetric distribution is lost can a population with increased Annexin V staining be detected. As shown in Fig. 3B and C, FACS analysis of oe-ST6Gal-I cells showed only low surface staining for Annexin V, but Annexin V staining was distinctly higher in sh-ST6Gal-I and vector cells after treatment with paclitaxel. A small population of oe-ST6Gal-I cells showed apoptosis (both early- and late-stage), whereas sh-ST6Gal-I cells had a large population undergoing apoptosis. Collectively, these results suggested that increased α2,6 sialylation in cancer cells reduced cell apoptosis and increased paclitaxel resistance.
α2,6 sialylation of FGFR1 affects the ERK and FAK signaling pathways. FGFR1 signaling was significantly correlated with tumorigenesis and metastasis in different types of cancer (10,17). A previous study demonstrated that FGFR1 phosphorylation can activate downstream ERK signaling cascades, which play a vital role in the proliferation and survival of cancer cells (36). Prior findings strongly suggested that FGFR1 and β3 integrin work in a complex, leading to the activation of FAK signaling to drive tumor metastasis. To investigate whether α2,6 sialylation of FGFR1...
OU et al: HIGH SIALYLATION OF FGFR1 PROMOTES OVARIAN CANCER CHEMORESISTANCE

Figure 3. Cells with high ST6Gal-I expression have reduced apoptosis and increased chemoresistance. (A) Inhibition rates of oe-ST6Gal-I and sh-ST6Gal-I cells treated with different concentrations of paclitaxel were assessed by a Cell Counting Kit-8 assay. (B) Quantitative analysis of apoptotic populations of oe-ST6Gal-I and sh-ST6Gal-I cells treated with or without paclitaxel; each analysis was performed in triplicate. *P<0.05. (C) Representative apoptotic populations of oe-ST6Gal-I and sh-ST6Gal-I cells treated with or without paclitaxel were stained with FITC Annexin V and 7-AAD. Lower right quadrant, Annexin V positive; upper right quadrant, Annexin V and 7-AAD positive. ST6Gal-I, α2,6-sialytransferase; oe, overexpression; sh, small hairpin; 7-AAD, 7-aminoactinomycin D; PE, phycoerythrin; PI, propidium iodide.

affected FGFR1 phosphorylation and the downstream ERK and FAK signaling pathways, a western blotting assay was used to detect the protein levels of FGFR1, ERK and FAK in oe-ST6Gal-I and sh-ST6Gal-I cells with or without paclitaxel treatment. As shown in Fig. 4A and B, α2,6-sialylated proteins in oe-ST6Gal-I and sh-ST6Gal-I cells bound by SNA-agarose were isolated by SDS-PAGE and immunoblotted for FGFR1. The SNA precipitation results demonstrated that SNA-FGFR1 expression was notably higher in oe-ST6Gal-I cells than in sh-ST6Gal-I cells. ST6Gal-I overexpression in hypersialylated FGFR1 cells, and paclitaxel treatment attenuated this effect. p-FGFR1 expression was notably lower in oe-ST6Gal-I cells than in sh-ST6Gal-I cells, and p-FGFR1 expression was enhanced after 10 μM paclitaxel treatment. The total FGFR1 expression was similar in each group (Fig. 4A and C). ERK1/2 and FAK phosphorylation levels were higher in oe-ST6Gal-I cells than in sh-ST6Gal-I cells, and paclitaxel decreased ERK and FAK phosphorylation levels in cancer cells, especially in sh-ST6Gal-I cells (Fig. 4A, D and E). The present results showed that ST6Gal-I overexpression in cancer cells increased the α2,6 sialylation of proteins and decreased the phosphorylation of FGFR1. Both α2,6 sialylation and phosphorylation of FGFR1 can activate downstream ERK and FAK signaling. Therefore, it was suggested that the decreased FGFR1 phosphorylation did not attenuate the effect of high α2,6 sialylation on downstream cascade activation.
High ST6Gal-I expression attenuates FGFR1 inhibitor-induced cell apoptosis. Since aberrant FGFR activity has been implicated in various cancer types, several FGFR inhibitors are currently in the early phases of clinical development (37). PDI73074 has reportedly shown both high affinity and selectivity for the FGFR family, and is being used as an FGFR inhibitor in the clinical settings and in experiments (38,39). The CCK-8 assay results showed that PDI73074 inhibited cancer cell growth in a dose-dependent manner, and the inhibition rate was lower in oe-ST6Gal-I cells than in sh-ST6Gal-I cells. Moreover, there was no significant difference between oe-ST6Gal-I cells and sh-ST6Gal-I cells when the concentration of PDI73074 reached 20 nM, and most of the cells died (Fig. 5A). The FACS results demonstrated that
the number of apoptotic cells (including early and late apoptotic cells) was increased with PD173074 treatment in oe-ST6Gal-I cells. The number of apoptotic sh-ST6Gal-I cells was notably higher with PD173074 treatment than the oe-ST6Gal-I cells (Fig. 5B and C). In agreement with the flow cytometry results, the western blotting results indicated that the apoptotic marker caspase-3 was significantly increased in sh-ST6Gal-I cells treated with PD173074, whereas caspase-3 levels in oe-ST6Gal-I cells were slightly increased after PD173074 treatment compared with vector cells (Fig. 5D and E).
together, these data suggested that FGFRI inhibitors can effectively induce cell death in vector cells and sh-ST6Gal-I cells; however, ST6Gal-I overexpression reduced this anticancer effect.

High ST6Gal-I expression protects cancer cells from Adriamycin. To further investigate the drug-resistant effects of ST6Gal-I on another chemotherapy drug, the inhibition rate of cells and cell apoptosis after treatment with Adriamycin were assessed. Similar to the paclitaxel results, the growth inhibition of Adriamycin was dose-dependent in each group. The growth inhibition was higher in sh-ST6Gal-I stable clone cells than in oe-ST6Gal-I cells at drug concentrations of 10-10000 nM (Fig. 6A). Furthermore, the FACS results showed that only a small population of oe-ST6Gal-I cells showed apoptosis (7.24%), whereas sh-ST6Gal-I cells had a large population undergoing apoptosis (29.34%) with Adriamycin treatment (Fig. 6B and C). In conclusion, ST6Gal-I overexpression enhances the chemoresistance of ovarian cancer cells; conversely, ST6Gal-I knockdown decreases chemoresistance.

Discussion

Ovarian cancer is characterized by a lack of early symptoms or screening methods, which often lead to late diagnosis in advanced stages and a high mortality rate (40). ST6Gal-I has been demonstrated to confer radiation resistance in colon cancer cell lines (41). However, the functional contribution of ST6Gal-I to ovarian cancer has yet to be elucidated. Accumulating evidence suggests that ST6Gal-I is a major inhibitor of cell death pathways initiated by Fas, TNFR1 and
Increased the operation, survival and migration (52, 53). In agreement with supports that FaK also plays a vital role in tumor cell proliferation resistance in cancer cells (50, 51). Accumulating evidence neoplasias, as well as poor prognosis and chemotherapeutic might be associated with the progression of a wide variety of angiogenesis in many cancer types (48, 49). ErK activation pathways, which are central to growth, survival migration and activation leads to downstream signaling via the ErK and FaK-mediated signaling pathways through other mechanisms. Therefore, further investigation is needed to thoroughly explore the underlying mechanism.

Multiple FGFR inhibitors are in development. Many of these are multi-targeted tyrosine kinase inhibitors against targeted receptors, including FGFR1 (54). In the present study, it was identified that the FGFR1 inhibitor PD173074 suppressed cancer cell proliferation and induced cell apoptosis; however, ST6Gal-I overexpression attenuated the effects of PD173074. Consistent with these results, ST6Gal-I overexpression also weakened the effect of Adriamycin on cancer cells. A hypothesis is that ST6Gal-I overexpression in cancer cells may protect cells from multiple apoptotic stimuli, thus promoting cell proliferation and migration.

In conclusion, the present data suggested that ST6Gal-I overexpression induces high levels of protein α2,6-sialylation and that FGFR1 is one of the targeted molecules. Sialylated FGFR1 activated the ERK and FAK pathways, thus promoting cell proliferation and migration. Overall, the present study provides new insight into how ST6Gal-I and FGFR1 signaling regulate cancer progression and drug resistance in ovarian cancer cells.

Acknowledgements

Not applicable.
24. Dall'Olio F, Malagolini N, Trinchera M and Chiricolo M: ST6Gal-I inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2. Oncol Lett 11: 4245-4251, 2016.

25. Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, Aletti G, Maddaluno L, Berezin V, Bock E, et al.: The adhesion molecule ncaM promotes ovarian cancer progression via FGFR signaling. EMBO Mol Med 3: 480-494, 2011.

26. Kamata N and Takata T: The FGFr1 inhibitor Pd173074 induces apoptosis in ovarian cancer cells. J Biol Chem 286: 5935-5941, 2011.

27. Huang W, Wei T, Fang J, Weng L, Li W, Jiang X, Ding T, Li X, Liang G, Cai Y and Ji J: Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer. BMC Cancer 15: 276, 2015.

28. Zhou Y and Bellis SL: Sialylation of beta integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J Biol Chem 283: 22177-22185, 2008.

29. Park JJ, Yi JY, Jin YB, Lee YJ, Lee JS, Ko YG and Lee M: Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to geteatin in colon cancer cells. Biochem Pharmacol 83: 849-857, 2012.

30. Gessi M, Monem YA, Hammes J, Goschitz K, Scholz M, Denkhaus D, Waha A and Pietsch T: FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle. Neuropathol Exp Neurol 73: 590-594, 2012.

31. Kim H and Bae S: FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73: 3716-3724, 2013.

32. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.

33. Cross SA, Sauro H, Chen J, Zhan F, Tomei L, Fournel-Fleury MC, Panek RL, GH, eliseenkova AV, Green D, Schlessinger J and Hubbard SR: Structure of an angiogenesis inhibitor bound to the FGFR tyrosine kinase domain. EMBO J 17: 5096-5104, 1998.

34. Hsu JJ, Lee JY, Kim SY, Park JJ, Yi JY, Lee YJ, Yoon YS, Ko YG and Lee M: Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to geteatin in colon cancer cells. Biochem Pharmacol 83: 849-857, 2012.

35. McKie AB, Vaughan S, Zanini E, Okon I, Louis L, de Sousa C, Friedl A, Rapraeger AC, McGown A, Slade J, et al.: The FGFR1 inhibitor Pd173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer 109: 2248-2258, 2013.

36. Briggs MI, Thompson ER, Sridhar A, Qiu W, Chong DY and Campbell IG: High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13: 4731-4739, 2007.

37. Whitworth MK, Backer AC, Clark AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade J, et al.: Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 11: 4282-4288, 2005.

38. Zweidler M, Bologa CS, Wang L, Zhu X, Qian H, Bologa G, Wang Y, Zhang L, Wang N, Shao H, et al.: FGFR1 is essential for ovarian cancer progression and metastasis. Cancer Res 73: 1316-1325, 2013.

39. Kaur S, Lee JS, Bae S and Lee YS: Protein sialylation by sialyltransferase involves radiation resistance. Mol Cancer Res 6: 3138-3143, 2012.

40. Chao X, Zhou Y, Chen YU and Yu F: miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2. Oncol Lett 11: 4245-4251, 2016.

41. Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, Wang F and Rowley DR: FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73: 3716-3724, 2013.

42. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM and Rosen JM: Inducible dimerization of FGFR1: Development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 157: 703-714, 2002.

43. Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, dall'Olio F, Malagolini N, Trinchera M and Chiricolo M: Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark ed) 17: 670-699, 2012.

44. McKie AB, Vaughan S, Zanini E, Okon I, Louis L, de Sousa C, Friedl A, Rapraeger AC, McGown A, Slade J, et al.: The o PcMl tumor suppressor functions as a cell surface angiogenesis inhibitor. Biochim Biophys Acta 1840: 2752-2764, 2014.

45. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S and Delannoy P: The human sialyltransferase family. Biochemie 83: 727-737, 2001.

46. Lee M, Park JJ and Lee YS: Adhesion of ST6Gal-I 1-mediated ovarian human cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation. Oncol Rep 23: 757-761, 2010.

47. Swindall AF and Bellis SL: Sialylation of the Fas death receptor by ST6Gal-I protects against Fas-induced apoptosis in colon carcinoma cells. J Biol Chem 286: 22982-22990, 2011.
48. Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC. Cancer Res 75: 4398-4406, 2015.

49. Anderson HJ and Galileo DS: Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease LICAM-stimulated glioblastoma cell motility and proliferation. Cell Oncol (Dordr) 39: 229-242, 2016.

50. Wales CT, Taylor FR, Higa AT, McAllister HA and Jacobs AT: ERK-dependent phosphorylation of HSF1 mediates chemo-therapeutic resistance to benzimidazole carbamates in colorectal cancer cells. Anticancer Drugs 26: 657-666, 2015.

51. Xiao Z, Ding N, Xiao G, Wang S, Wu Y and Tang L: Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line. Anat Rec (Hoboken) 295: 2122-2128, 2012.

52. Zhang J and Hochwald SN: The role of FAK in tumor metabolism and therapy. Pharmacol Ther 142: 154-163, 2014.

53. Lee BY, Timpson P, Horvath LG and Daly RJ: FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 146: 132-149, 2015.

54. Katoh M: FGFR inhibitors: Effects on cancer cells, tumor micro-environment and whole-body homeostasis (Review). Int J Mol Med 38: 3-15, 2016.